Cover Image
市場調查報告書

急性骨髓灰白質炎 (小兒麻庳) :開發中產品分析

Poliomyelitis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 362372
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
急性骨髓灰白質炎 (小兒麻庳) :開發中產品分析 Poliomyelitis - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 81 Pages
簡介

本報告提供急性骨髓灰白質炎 (小兒麻庳) 治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

急性骨髓灰白質炎 (小兒麻庳)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

急性骨髓灰白質炎 (小兒麻庳) :企業開發中的治療藥

急性骨髓灰白質炎 (小兒麻庳) :大學/機關研究中的治療藥

急性骨髓灰白質炎 (小兒麻庳) :開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

急性骨髓灰白質炎 (小兒麻庳) :企業開發中的產品

急性骨髓灰白質炎 (小兒麻庳) :大學/機關研究中的產品

急性骨髓灰白質炎 (小兒麻庳)的治療藥的開發企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Bilthoven Biologicals B.V.
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • Codagenix, Inc.
  • 第一三共
  • Grifols, S.A.
  • Johnson & Johnson
  • LG Life Science LTD.
  • Nanolek, LLC
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Sentinext Therapeutics Sdn Bhd
  • Sinovac Biotech Ltd.
  • Taiga Biotechnologies, Inc.

急性骨髓灰白質炎 (小兒麻庳) :治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

急性骨髓灰白質炎 (小兒麻庳) :最近的開發平台趨勢

急性骨髓灰白質炎 (小兒麻庳) :暫停中的計劃

急性骨髓灰白質炎 (小兒麻庳) :開發中止的產品

急性骨髓灰白質炎 (小兒麻庳) :產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8182IDB

Summary

Global Markets Direct's, 'Poliomyelitis - Pipeline Review, H1 2016', provides an overview of the Poliomyelitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poliomyelitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Poliomyelitis
  • The report reviews pipeline therapeutics for Poliomyelitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Poliomyelitis therapeutics and enlists all their major and minor projects
  • The report assesses Poliomyelitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Poliomyelitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Poliomyelitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poliomyelitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Poliomyelitis Overview
  • Therapeutics Development
    • Pipeline Products for Poliomyelitis - Overview
    • Pipeline Products for Poliomyelitis - Comparative Analysis
  • Poliomyelitis - Therapeutics under Development by Companies
  • Poliomyelitis - Therapeutics under Investigation by Universities/Institutes
  • Poliomyelitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Poliomyelitis - Products under Development by Companies
  • Poliomyelitis - Products under Investigation by Universities/Institutes
  • Poliomyelitis - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Beijing Tiantan Biological Products Co., Ltd.
    • Bharat Biotech International Limited
    • Bilthoven Biologicals B.V.
    • Biological E. Limited
    • Boryung Pharmaceutical Co., Ltd.
    • Codagenix, Inc.
    • Daiichi Sankyo Company, Limited
    • Grifols, S.A.
    • Johnson & Johnson
    • LG Life Science LTD.
    • Nanolek, LLC
    • Panacea Biotec Limited
    • Sanofi Pasteur SA
    • Sentinext Therapeutics Sdn Bhd
    • Sinovac Biotech Ltd.
    • Taiga Biotechnologies, Inc.
  • Poliomyelitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + poliovirus + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ImmunoRx - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPVGVI-3000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LBVC - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio (virus like particle, bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio [serotypes 1, 2, 3] (monovalent) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio [strain Sabin] vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • polio vaccine 2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • poliomyelitis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Poliomyelitis - Recent Pipeline Updates
  • Poliomyelitis - Dormant Projects
  • Poliomyelitis - Discontinued Products
  • Poliomyelitis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine
      • Mar 03, 2014: Inactivated Polio Vaccines Broadly Available for the World's Children in the Drive Toward Polio Eradication
      • Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima
      • Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine
      • Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Poliomyelitis, H1 2016
  • Number of Products under Development for Poliomyelitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • Poliomyelitis - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016
  • Poliomyelitis - Pipeline by Bharat Biotech International Limited, H1 2016
  • Poliomyelitis - Pipeline by Bilthoven Biologicals B.V., H1 2016
  • Poliomyelitis - Pipeline by Biological E. Limited, H1 2016
  • Poliomyelitis - Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016
  • Poliomyelitis - Pipeline by Codagenix, Inc., H1 2016
  • Poliomyelitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Poliomyelitis - Pipeline by Grifols, S.A., H1 2016
  • Poliomyelitis - Pipeline by Johnson & Johnson, H1 2016
  • Poliomyelitis - Pipeline by LG Life Science LTD., H1 2016
  • Poliomyelitis - Pipeline by Nanolek, LLC, H1 2016
  • Poliomyelitis - Pipeline by Panacea Biotec Limited, H1 2016
  • Poliomyelitis - Pipeline by Sanofi Pasteur SA, H1 2016
  • Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2016
  • Poliomyelitis - Pipeline by Sinovac Biotech Ltd., H1 2016
  • Poliomyelitis - Pipeline by Taiga Biotechnologies, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Poliomyelitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Poliomyelitis - Dormant Projects, H1 2016
  • Poliomyelitis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Poliomyelitis, H1 2016
  • Number of Products under Development for Poliomyelitis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top